

SEQUENCE LISTING

<110> Roche Diagnostics GmbH
F. Hoffmann-La Roche AG

5 <120> Improved method for bisulfite treatment

<130> 21581 WO

10 <140>
<141>

<150> EP03001854.3
<151> 2003-01-29

15 <150> EP03010020.0
<151> 2003-05-02

<160> 8

20 <170> PatentIn Ver. 2.1

<210> 1
<211> 20

25 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:sense strand

30 <400> 1
gaggggcgcc ctggagtccc 20

35 <210> 2
<211> 20
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Description of Artificial Sequence:antisense
strand

<400> 2

45 gggactccag ggcgcccctc 20

<210> 3
<211> 20

50 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:sense strand, c
55 converted to n, n denotes deoxyuracil

<400> 3
gaggggngnn ntggagtnnn 20

5 <210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence:antisense
strand, c converted to n, n denotes deoxyuracil

<400> 4
15 gggantnnag ggngnnnntn 20

<210> 5
<211> 11
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:synthesized
25 oligonucleotide

<400> 5
tttttctttt t 11

30 <210> 6
<211> 11
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence:synthesized
oligonucleotide, c in position 6 is methylated

40 <400> 6
tttttctttt t 11

<210> 7
45 <211> 11
<212> DNA
<213> Artificial Sequence

<220>
50 <223> Description of Artificial Sequence:synthesized
oligonucleotide, c converted to n, n denotes
deoxyuracil

<400> 7
55 tttttntttt t 11

<210> 8
<211> 11
<212> DNA
5 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:synthesized
oligonucleotide

10

<400> 8
tttttttttt t

11